Cagrilintide: The Long-Acting Amylin Analog for Satiety Research

Cagrilintide represents a significant advancement in amylin-based metabolic therapeutics—a 37-amino-acid engineered peptide designed to overcome the limitations of first-generation amylin analogs. Developed by Novo Nordisk, this long-acting amylin receptor agonist has demonstrated promising weight loss efficacy in clinical trials, both as monotherapy and in combination with semaglutide (as CagriSema). Cagrilintide works through mechanisms distinct from GLP-1 receptor agonists, offering researchers a complementary tool for investigating multi-pathway approaches to obesity and metabolic disease.

The development of Cagrilintide addresses a fundamental gap in obesity pharmacology. While GLP-1 agonists have transformed weight management, they represent only one of multiple physiological pathways regulating energy balance. Amylin, a pancreatic hormone co-secreted with insulin, provides independent satiety signaling through brainstem receptors. By creating a long-acting amylin analog suitable for once-weekly dosing, Cagrilintide enables practical research into this underexplored pathway.

Molecular Structure and Engineering

Cagrilintide is a 37-amino-acid peptide based on the structure of human amylin (islet amyloid polypeptide, IAPP), a naturally occurring hormone secreted by pancreatic beta cells alongside insulin. However, native amylin has poor pharmaceutical properties—it aggregates readily and has a short plasma half-life. Cagrilintide incorporates strategic modifications to address these limitations:

Proline Substitutions: Multiple proline residues replace native amino acids at positions 25, 28, and 29 (and potentially others). These substitutions disrupt beta-sheet formation and reduce amyloid fibril propensity, preventing the aggregation that limits native amylin’s utility. Similar proline substitutions in pramlintide (the first-generation amylin analog) established this approach, but Cagrilintide extends the strategy with additional modifications.

Helix-Stabilizing Mutations: The peptide incorporates 14E/17R mutations designed to stabilize the central alpha-helix through salt bridge formation. This structural enhancement improves receptor binding and biological activity.

C-Terminal Proline: A C-terminal proline residue enhances potency specifically at calcitonin receptors, contributing to the dual receptor profile.

C20 Fatty Acid Acylation: An N-terminal C20 fatty diacid moiety enables albumin binding, extending the plasma half-life from minutes (native amylin) or hours (pramlintide) to approximately 5-6 days. This modification transforms Cagrilintide into a true once-weekly therapeutic.

The resulting molecule retains amylin’s biological activity while gaining pharmaceutical acceptability—resistant to aggregation, stable in formulation, and suitable for sustained delivery.

Mechanism of Action: Amylin Receptor Signaling

Cagrilintide exerts its effects primarily through activation of amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors (CTR), making it a dual amylin/calcitonin receptor agonist (DACRA). These receptors are expressed in key brain regions that regulate feeding behavior and energy homeostasis.

The primary site of action is the area postrema, a circumventricular organ in the brainstem that lacks a complete blood-brain barrier. Here, Cagrilintide activates amylin receptors on neurons that project to the nucleus of the solitary tract and other feeding centers. The resulting neural activation triggers:

• Satiety signaling: Rapid onset of meal termination and reduced food intake, distinct from the slower gastric emptying effects of GLP-1
• Postprandial glucose control: Delayed gastric emptying and suppression of post-meal glucagon secretion
• Energy expenditure modulation: Potential effects on thermogenesis and metabolic rate through central pathways

Importantly, amylin signaling operates independently of GLP-1 pathways. While GLP-1 acts on hypothalamic appetite centers through different receptor mechanisms, amylin provides parallel satiety input from the brainstem. This independence explains why combining Cagrilintide with semaglutide (CagriSema) produces additive effects—the two peptides target different neural circuits.

Clinical Research and Efficacy Data

Cagrilintide has advanced through extensive clinical development, with data from Phase 2 and Phase 3 trials demonstrating significant efficacy:

Monotherapy Results: In the REDEFINE 1 Phase 3 trial, Cagrilintide monotherapy produced 11.8% weight loss after 68 weeks of treatment. Earlier Phase 2 data showed approximately 10.8% weight loss at 26 weeks versus 3.0% for placebo. These results establish Cagrilintide as an effective standalone obesity treatment.

Combination Therapy (CagriSema): The combination of Cagrilintide 2.4 mg with semaglutide 2.4 mg (CagriSema) achieved remarkable 20.4% weight loss in Phase 3 trials—substantially exceeding the efficacy of either component alone. This combination represents the first once-weekly GLP-1/amylin dual therapy and has been submitted for FDA approval.

Distinct Efficacy Profile: Clinical trial data suggests Cagrilintide produces weight loss through mechanisms complementary to GLP-1 agonists. The combination data supports the hypothesis that targeting multiple satiety pathways simultaneously enhances overall efficacy.

Safety Profile: Adverse events are consistent with other gut peptide therapies, with nausea, vomiting, and diarrhea being most common, particularly during dose escalation. The safety profile appears manageable and similar to established amylin and GLP-1 analogs.

Cagrilintide vs. Pramlintide and Other Amylin Analogs

Understanding Cagrilintide’s position requires comparison with existing amylin-based therapies:

Pramlintide (Symlin) is the first-generation amylin analog approved for diabetes management. It requires multiple daily injections due to its short half-life (~48 minutes) and has modest efficacy for weight loss. Cagrilintide represents a quantum improvement, with once-weekly dosing and substantially greater weight loss efficacy.

Native Amylin has theoretical therapeutic potential but is impractical due to rapid aggregation and short half-life. Cagrilintide’s proline substitutions specifically address the aggregation problem.

GLP-1 Agonists like semaglutide work through different mechanisms. While both classes reduce food intake, amylin acts more rapidly on meal termination while GLP-1 provides more sustained appetite suppression. This pharmacological complementarity underlies the success of the CagriSema combination.

Dual Amylin/Calcitonin Receptor Agonists (DACRAs) represent a broader class that includes Cagrilintide and other investigational compounds. The calcitonin receptor component may contribute to additional metabolic effects beyond pure amylin agonism.

Preclinical Research Findings

The development of Cagrilintide was guided by extensive preclinical research characterizing its pharmacological properties. Studies published in the Journal of Medicinal Chemistry demonstrated:

• Superior duration: A single 3 nmol/kg dose of Cagrilintide reduced food intake by ~50% for 48-60 hours in rats, compared to 6-hour duration for pramlintide at much higher doses
• Enhanced potency: Cagrilintide achieved greater and more sustained food intake reduction than pramlintide at equivalent or lower doses
• Receptor binding: Structural studies revealed optimized binding to both amylin and calcitonin receptors

Research published in Nature Communications provided detailed structural insights into Cagrilintide binding to calcitonin and amylin receptors, revealing the molecular basis for its dual agonist activity and long receptor residence time.

Research Applications and Considerations

Laboratories investigating Cagrilintide have a unique tool for studying amylin receptor pharmacology and its role in energy homeostasis. Research applications include:

• Satiety mechanisms: Investigating brainstem versus hypothalamic pathways for appetite regulation
• Combination studies: Exploring interactions with GLP-1, leptin, and other metabolic hormones
• Glucose metabolism: Studying effects on postprandial glucose, gastric emptying, and glucagon secretion
• Receptor pharmacology: Characterizing AMY versus CTR contributions to biological effects
• Comparative efficacy: Head-to-head studies with pramlintide and other amylin analogs

The once-weekly dosing profile simplifies research protocols compared to daily or multiple-times-daily peptides. However, the extended half-life means that drug accumulation and steady-state pharmacokinetics must be considered in study design.

Standard reconstitution uses bacteriostatic water, with storage of lyophilized powder under refrigeration. The C20 fatty acid modification gives Cagrilintide different solubility characteristics than unacylated peptides, potentially requiring optimization of formulation conditions.

Current Status and Future Directions

As of 2026, Cagrilintide is in advanced clinical development. Novo Nordisk has submitted CagriSema (Cagrilintide + semaglutide) for FDA approval based on Phase 3 data. The REIMAGINE clinical program continues to evaluate Cagrilintide across multiple indications and patient populations.

The success of Cagrilintide validates the amylin pathway as a therapeutic target for obesity and establishes proof-of-concept for long-acting amylin analogs. Future research directions include:

• Expanded indications: Type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and other metabolic conditions
• Next-generation analogs: Further optimization of receptor selectivity and pharmacokinetic properties
• Combination approaches: Triple and quadruple hormone combinations targeting multiple metabolic pathways
• Mechanism studies: Elucidating the relative contributions of amylin versus calcitonin receptor activation

For research laboratories, Cagrilintide represents the state-of-the-art in amylin-based metabolic research, offering once-weekly dosing and robust efficacy that enables practical investigation of this important hormonal pathway.

Explore our comprehensive selection of research peptides and metabolic compounds for your laboratory studies. Visit our homepage to discover the latest additions to our research catalog.

References

• “Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.” PubMed. https://pubmed.ncbi.nlm.nih.gov/36883831/
• “Development of Cagrilintide, a Long-Acting Amylin Analogue.” Journal of Medicinal Chemistry, ACS Publications. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
• “Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.” Nature Communications. https://www.nature.com/articles/s41467-025-58680-y
• “Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.” NCBI PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12085449/
• “Cagrilintide.” Wikipedia. https://en.wikipedia.org/wiki/Cagrilintide

Disclaimer: This product is sold for laboratory research purposes only. Cagrilintide is not intended for human consumption, medical treatment, or diagnostic use. It is an investigational compound with regulatory status pending. This information is provided for educational purposes and does not constitute medical or scientific advice. Always consult relevant scientific literature and follow proper laboratory safety protocols.